Press Releases
Endo Pharmaceuticals Announces That FDA Eliminates Need for Advisory Committee Meeting to Discuss New Formulation of Long-Acting Oxymorphone
 Endo Pharmaceuticals announced that the U.S. FDA has informed the company that FDA no longer sees a need to convene a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk...
Press Releases
Abbott Wins Two Scrip Awards Recognizing Excellence in Pharmaceutical and Biotech Industries
Abbott Park, Illinois Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management. Miles D. White, chairman and chief executive officer, Abbott said,...
Press Releases
Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma
Nycomed announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in...
Press Releases
PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia
PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia (nmMMA). MMA is a rare genetic disorder caused...
Press Releases
Celator Pharmaceuticals completes enrollment in a second phase 2 trail of CPX-351in acute myeloid leukemia
Celator Pharmaceuticals announced that it has completed enrollment in a phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients with acute myeloid leukemia (AML) in first relapse. The study,...
Press Releases
Eurand Presents Data on ZENPEP(R) Without Proton Pump Inhibitors or H2 Receptor Antagonists in Patients With CF and Pancreatic Insufficiency
Eurand Pharmaceuticals, Inc., a subsidiary of global specialty pharmaceutical company Eurand N.V. announced additional data from a post-hoc analysis of a Phase III clinical trial with ZENPEP(R) (pancrelipase) Delayed-Release Capsules, an FDA-approved pancreatic enzyme product (PEP) for the treatment...
Press Releases
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Cephalon, Inc. (Nasdaq: CEPH) today announced that Risk Evaluation and Mitigation Strategies (REMS) for its medications NUVIGIL(R) (armodafinil) Tablets and PROVIGIL(R) (modafinil) Tablets have been approved by the U.S. Food and Drug Administration (FDA). Both the NUVIGIL...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read